EverInsight Therapeutics, Inc.

Amid increasingly hot competition for oncology drugs, a new crop of biotechs are looking at CNS conditions and AffaMed Therapeutics , backed by CBC group (formerly C-Bridge Capital) has licensed excl

VistaGen Therapeutics, Inc. has rebounded from clinical development setbacks before, but investors imposed a severe penalty on the South San Francisco biotech on 22 July following its pre-market anno

Biopharmaceutical companies raised $1.5bn in 11 venture capital mega-rounds of $100m or more during the last week and a half of March. Including VC and other financings under $100m, 35 privately held

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Curon Picks Up China-Plus Rights to Rhi